Trademark applications and grants for Xtl Biopharmaceuticals L T D. Xtl Biopharmaceuticals L T D has 8 trademark applications. The latest application filed is for "HEPEX"
Patent Application | Date |
---|---|
PHARMACEUTICAL COMPOSITIONS COMPRISING 0.25 MG DOSE OF SYNTHETIC HUMAN PEPTIDES FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS 20200338195 - 16/930924 UROWITZ; Murray B. ;   et al. | 2020-10-29 |
PHARMACEUTICAL COMPOSITIONS COMPRISING 0.5 MG DOSE OF SYNTHETIC HUMAN PEPTIDES FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS 20180043017 - 15/673642 UROWITZ; Murray B. ;   et al. | 2018-02-15 |
PHARMACEUTICAL COMPOSITIONS COMPRISING 0.25 MG DOSE OF SYNTHETIC HUMAN PEPTIDES FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS 20180043016 - 15/673555 UROWITZ; Murray B. ;   et al. | 2018-02-15 |
Treatment of hepatitis B virus infection with human monoclonal antibodies 20050260195 - 11/056186 Dagan, Shlomo ;   et al. | 2005-11-24 |
SEC | 0001023549 | XTL BIOPHARMACEUTICALS LTD of ISRAEL |
SEC | 0001696804 | XTL Biopharmaceuticals Ltd/ADR |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.